Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 9, Pages e107587
Publisher
Public Library of Science (PLoS)
Online
2014-09-23
DOI
10.1371/journal.pone.0107587
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
- (2013) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
- (2013) Monique Terwijn et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse
- (2012) C Bachas et al. LEUKEMIA
- The proportion of CD34+CD38low or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia
- (2012) M Roshal et al. LEUKEMIA
- Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
- (2011) F. Buccisano et al. BLOOD
- Leukemia stem cells in 2010: Current understanding and future directions
- (2011) Michael W. Becker et al. BLOOD REVIEWS
- Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
- (2011) Nicolas Goardon et al. CANCER CELL
- Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical significance
- (2011) Dan Ran et al. EXPERIMENTAL HEMATOLOGY
- High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
- (2011) F. Vergez et al. HAEMATOLOGICA
- High Proportion of Leukemic Stem Cells at Diagnosis Is Correlated with Unfavorable Prognosis in Childhood Acute Myeloid Leukemia
- (2011) Kai-Erik Witte et al. PEDIATRIC HEMATOLOGY AND ONCOLOGY
- Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
- (2011) M. Jan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction
- (2010) D. C. Taussig et al. BLOOD
- Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice
- (2010) Jean-Emmanuel Sarry et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells
- (2010) Y. Saito et al. Science Translational Medicine
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes
- (2009) Dan Ran et al. EXPERIMENTAL HEMATOLOGY
- Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
- (2008) D. C. Taussig et al. BLOOD
- Stem cell concepts renew cancer research
- (2008) J. E. Dick BLOOD
- Identification of a Small Subpopulation of Candidate Leukemia-Initiating Cells in the Side Population of Patients with Acute Myeloid Leukemia
- (2008) Bijan Moshaver et al. STEM CELLS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started